ATE540010T1 - Therapeutische verbindungen - Google Patents

Therapeutische verbindungen

Info

Publication number
ATE540010T1
ATE540010T1 AT08769340T AT08769340T ATE540010T1 AT E540010 T1 ATE540010 T1 AT E540010T1 AT 08769340 T AT08769340 T AT 08769340T AT 08769340 T AT08769340 T AT 08769340T AT E540010 T1 ATE540010 T1 AT E540010T1
Authority
AT
Austria
Prior art keywords
therapeutic compounds
treatment
promoting
migraine
anesthetic
Prior art date
Application number
AT08769340T
Other languages
English (en)
Inventor
Thomas Jenkins
Original Assignee
Pharmacofore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacofore Inc filed Critical Pharmacofore Inc
Application granted granted Critical
Publication of ATE540010T1 publication Critical patent/ATE540010T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06—Alkylated phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/20—Diazonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
    • C07C37/003—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by hydrogenation of an unsaturated part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/045—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis by substitution of a group bound to the ring by nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/86—Purification; separation; Use of additives, e.g. for stabilisation by treatment giving rise to a chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08769340T 2007-05-09 2008-05-08 Therapeutische verbindungen ATE540010T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92841607P 2007-05-09 2007-05-09
US92834507P 2007-05-09 2007-05-09
PCT/US2008/063088 WO2008141099A1 (en) 2007-05-09 2008-05-08 Therapeutic compounds

Publications (1)

Publication Number Publication Date
ATE540010T1 true ATE540010T1 (de) 2012-01-15

Family

ID=39619201

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08769340T ATE540010T1 (de) 2007-05-09 2008-05-08 Therapeutische verbindungen

Country Status (18)

Country Link
US (3) US8173849B2 (de)
EP (2) EP2152651B1 (de)
JP (1) JP2010526827A (de)
KR (1) KR20100017435A (de)
CN (1) CN101687746A (de)
AT (1) ATE540010T1 (de)
AU (1) AU2008251484A1 (de)
BR (1) BRPI0811284A2 (de)
CA (1) CA2685813A1 (de)
DK (1) DK2152651T3 (de)
ES (1) ES2380824T3 (de)
HK (1) HK1138830A1 (de)
IL (1) IL201735A0 (de)
MX (1) MX2009012125A (de)
MY (1) MY147215A (de)
RU (1) RU2470907C2 (de)
WO (1) WO2008141099A1 (de)
ZA (1) ZA201007602B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2146946T3 (pl) 2007-05-09 2011-04-29 Pharmacofore Inc (-)-Stereoizomer 2,6-di-sec-butylofenolu i jego analogi
WO2009140275A1 (en) * 2008-05-12 2009-11-19 Pharmacofore, Inc. Analogs of propofol, preparation thereof and use as anesthetics
CN102085185B (zh) * 2010-12-07 2013-04-24 西安力邦制药有限公司 无痛和低注射刺激的新型丙泊酚脂肪乳制剂配方和制备方法
CN102603488B (zh) * 2012-03-06 2017-01-04 云南龙海天然植物药业有限公司 一种制备高纯度丙泊酚的新方法
CN102731265B (zh) * 2012-06-12 2014-12-10 四川百利药业有限责任公司 一种高纯度丙泊酚的制备方法
CN104768918B (zh) * 2012-11-02 2017-03-08 住友化学株式会社 化合物的外消旋体的制造方法
CN104649867B (zh) * 2013-11-21 2017-02-15 辽宁药联制药有限公司 一种丙泊酚的制备方法
CN105384608B (zh) * 2014-08-22 2019-08-16 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
CN105384604B (zh) * 2014-08-22 2019-07-05 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
CN105384607B (zh) * 2014-08-22 2019-08-16 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
AU2015311394B2 (en) * 2014-09-04 2018-11-08 Haisco Innovative Pharmaceutical Pte. Ltd. Use of GABAA receptor reinforcing agent in preparation of sedative and anesthetic medicament
CN105820040B (zh) * 2015-01-22 2018-07-24 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法
CN106278947B (zh) * 2015-05-19 2020-03-06 四川海思科制药有限公司 苯酚衍生物的晶型及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2747982A (en) * 1955-05-11 1956-05-29 Dow Chemical Co Method and composition for the control of the growth of vegetation
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
SU1525139A1 (ru) * 1987-11-10 1989-11-30 Куйбышевский политехнический институт им.В.В.Куйбышева Способ получени о-втор-бутилфенола
ES2087019B1 (es) * 1994-02-08 1997-03-16 Bobel246 S L Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
US5731356A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
AU3000800A (en) 1999-02-18 2000-09-04 Supergen, Inc. Phosphocholine linked prodrug derivatives
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6362234B1 (en) 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7144877B2 (en) 2000-10-06 2006-12-05 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2002254309B2 (en) * 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
UA76802C2 (uk) 2001-12-28 2006-09-15 Мгі Гп, Інк. Фармацевтичний препарат водорозчинних проліків пропофолу на водній основі (варіанти)
US7035343B2 (en) 2002-01-31 2006-04-25 Qualcomm Inc. Closed loop transmit diversity antenna verification using trellis decoding
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
BG65734B1 (bg) 2002-02-22 2009-09-30 Био Терапютикс - Еоод Течен мукоадхезивен фармацевтичен състав
RU2297216C2 (ru) 2002-04-08 2007-04-20 Эм-Джи-Ай Джи-Пи,Инк. Фармацевтические композиции, содержащие растворимые в воде пролекарства пропофола, и способы их применения
EP1549350B1 (de) 2002-10-08 2008-09-24 Fresenius Kabi Deutschland GmbH Pharmazeutisch aktive oligosaccharid-conjugate
DE20215415U1 (de) 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
ZA200504940B (en) 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US7230003B2 (en) 2003-09-09 2007-06-12 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US20070043121A1 (en) * 2003-09-29 2007-02-22 Brown Milton L Discovery of novel soluble crystalline anesthetics
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
EP1791521A4 (de) 2004-09-17 2009-10-21 Eisai Corp North America Verfahren zum verabreichen von wasserlöslichen prodrugs von propofol
JP2008525501A (ja) 2004-12-23 2008-07-17 ゼノポート，インコーポレイティド セリンアミノ酸誘導のプロポフォールのプロドラッグ、その使用及び結晶体
DE102005033496A1 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel
CA2632561C (en) * 2005-12-19 2015-01-27 The University Of Liverpool Substituted propofol derivatives as analgesics
US7535698B2 (en) 2006-03-07 2009-05-19 Panasonic Corporation Case, portable information equipment using the same and manufacturing method of the case
US7731356B1 (en) * 2006-07-24 2010-06-08 Daniel Ayers Gilbert Hanging eyeglasses

Also Published As

Publication number Publication date
JP2010526827A (ja) 2010-08-05
EP2392559A1 (de) 2011-12-07
CA2685813A1 (en) 2008-11-20
HK1138830A1 (en) 2010-09-03
MX2009012125A (es) 2010-02-18
CN101687746A (zh) 2010-03-31
US20100249246A1 (en) 2010-09-30
RU2470907C2 (ru) 2012-12-27
KR20100017435A (ko) 2010-02-16
IL201735A0 (en) 2010-06-16
US20120196939A1 (en) 2012-08-02
US8173849B2 (en) 2012-05-08
BRPI0811284A2 (pt) 2015-01-20
ES2380824T3 (es) 2012-05-18
ZA201007602B (en) 2012-08-29
US8350097B2 (en) 2013-01-08
WO2008141099A1 (en) 2008-11-20
EP2152651A1 (de) 2010-02-17
EP2152651B1 (de) 2012-01-04
AU2008251484A1 (en) 2008-11-20
MY147215A (en) 2012-11-14
DK2152651T3 (da) 2012-04-10
US20130217783A1 (en) 2013-08-22
RU2009145541A (ru) 2011-06-20

Similar Documents

Publication Publication Date Title
ATE540010T1 (de) Therapeutische verbindungen
EA201100447A1 (ru) Органические соединения
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
ECSP11010980A (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
MX2009009492A (es) Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
EA201290089A1 (ru) Химические соединения
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
UY31803A (es) Compuesto cristalino
BR0311494A (pt) Novos indóis substituìdos
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
ATE554089T1 (de) Spirocyclische cyclohexan-derivate
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
DK2215058T3 (da) Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf
EA201000633A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
MX2009012222A (es) Dihidroquinonas y dihidronaftiridinas como inhibidores de las quinasas c-jun-n-terminales.
UA107562C2 (uk) Спосіб лікування псоріазу
MX2011011776A (es) Nuevos profarmacos de triptolite.
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
MX2009013749A (es) Forma cristalina de [3-(4,5-dihidro-3-isoxazolil)-2-metil-4-(metil sulfonil)fenil]-(5-hidroxi-1-metil-1h-pirazol-4-il)metanona.
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
HK1156019A1 (en) (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect, treatment of nausea and vomiting and treatment of migraine (-)- 26-
DE602005026965D1 (de) Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete aminomethylsubstituierte bicyclische aromatische verbindungen